Oct 2026· Biosensors· Vol 16, pp. 612· 0 citations· 33 references
TL;DR
Results support the potential of the antibody-functionalized ESDI platform for label-free detection of CD44-expressing cells, providing a groundwork for its validation in clinical samples as a step toward tumor-cell diagnostics.
Abstract
Breast cancer remains a major cause of cancer-related mortality in women, and its substantial molecular heterogeneity highlights the need for methods capable of characterizing tumor cells at the cellular level. CD44, a transmembrane glycoprotein associated with breast cancer progression, metastasis, and cancer stem-like phenotypes, is a promising biomarker for selective recognition of aggressive, basal-like cell populations. However, conventional approaches to evaluating CD44 expression including immunohistochemistry, immunofluorescence, and flow cytometry require labeling and multi-step sample preparation. In this work, a gold-coated, polydimethylsiloxane (PDMS)-based extrinsic semi-distributed interferometric (SDI) optical fiber biosensor functionalized with anti-CD44 antibodies was developed for label-free, selective detection of CD44-expressing HCC1806 breast cancer cells. The functionalized sensor exhibited a concentration-dependent response with a limit of detection (LoD) of 2.51 cells/mL, while the antibody-free control sensor exposed to HCC1806 cells and the anti-CD44-functionalized sensor exposed to CD44-low HEK293 cells showed only minimal responses, supporting selective detection under the tested conditions. These results support the potential of the antibody-functionalized ESDI platform for label-free detection of CD44-expressing cells, providing a groundwork for its validation in clinical samples as a step toward tumor-cell diagnostics.
The developed fiber-optic biosensors show potential for integration into liquid biopsy platforms for label-free detection of circulating tumor cells in biological fluids, providing a rapid and minimally invasive approach for cancer detection and monitoring.
Aigerim Omirzakova, Lyazzat Mukhangaliyeva, Marzhan Nurlankyzy et al.· Oncology, Nuclear Medicine a...· 0 citations
The development of a graphene oxide-coated fiber-optic biosensor based on a semi-distributed interferometric sensing platform for the highly sensitive detection of solCD44, a cell adhesion glycoprotein whose soluble form is elevated in several cancers including breast cancer, is reported.
K. Seitkamal, A. Bekmurzayeva, A. Aubakirova et al.· Oncology, Nuclear Medicine a...· 0 citations
Graphene oxide-coated semi-distributed interferometric biosensor is established as a highly sensitive platform for CD44 detection in clinically relevant samples and its potential for future development toward the detection of other circulating biomarkers is highlighted.
K. Seitkamal, A. Bekmurzayeva, Kanagat Kantoreyeva et al.· ACS Sensors· 0 citations
Early detection of cancer remains challenging due to the extremely low concentration of biomarkers present during initial disease stages. Dysregulation of key signaling pathways, including cyclin-dependent kinase (CDK) networks, drives uncontrolled cell proliferation and tumor progression, underscoring the need for hig...
Bocar Ndiaye, N. Brahiti, K. Nouri et al.· Italian National Conference...· 0 citations
Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer (BC), and the precise detection of MDA-MB-231 cells is important for the early diagnosis, disease monitoring, and evaluation of treatment efficacy in TNBC. However, traditional detection methods have disadvantages such as compl...
Jiao-Yan Qiu, Ying-Qi Chen, Yuan-Fei Wang et al.· Nanoscale· 0 citations
Introduction: The study of triple-negative breast cancer cells detection is one of the important research fields in modern biomedical engineering, due to its aggressive behavior and limited targeting options. One of the promising methods for cancer cell detection is using Molecularly Imprinted Polymers (MIPs) with poly...
Bakdaulet Yendibay, Akmaral Suleimenova, Aigerim Omirzakova et al.· Oncology, Nuclear Medicine a...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.